Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

Core Insights - Merck has entered into an agreement with Blackstone Life Sciences for funding to develop sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate targeting TROP2, a protein associated with various cancer cells [1] Company Summary - Merck, also known as MSD outside the U.S. and Canada, is focusing on the development of sac-TMT, which is currently being evaluated in 15 global clinical trials [1]